GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axcella Health Inc (OTCPK:AXLA) » Definitions » EV-to-EBIT

Axcella Health (Axcella Health) EV-to-EBIT : 0.14 (As of May. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Axcella Health EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Axcella Health's Enterprise Value is $-6.31 Mil. Axcella Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-46.67 Mil. Therefore, Axcella Health's EV-to-EBIT for today is 0.14.

The historical rank and industry rank for Axcella Health's EV-to-EBIT or its related term are showing as below:

AXLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.58   Med: 0   Max: 0.14
Current: 0.14

During the past 6 years, the highest EV-to-EBIT of Axcella Health was 0.14. The lowest was -2.58. And the median was 0.00.

AXLA's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.545 vs AXLA: 0.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Axcella Health's Enterprise Value for the quarter that ended in Jun. 2023 was $8.59 Mil. Axcella Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-46.67 Mil. Axcella Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -542.99%.


Axcella Health EV-to-EBIT Historical Data

The historical data trend for Axcella Health's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axcella Health EV-to-EBIT Chart

Axcella Health Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial - -0.46 -2.11 -0.84 -0.12

Axcella Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -1.26 -0.12 -0.39 -0.18

Competitive Comparison of Axcella Health's EV-to-EBIT

For the Biotechnology subindustry, Axcella Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axcella Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axcella Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Axcella Health's EV-to-EBIT falls into.



Axcella Health EV-to-EBIT Calculation

Axcella Health's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-6.311/-46.665
=0.14

Axcella Health's current Enterprise Value is $-6.31 Mil.
Axcella Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axcella Health  (OTCPK:AXLA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Axcella Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-46.665/8.594127325
=-542.99 %

Axcella Health's Enterprise Value for the quarter that ended in Jun. 2023 was $8.59 Mil.
Axcella Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axcella Health EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Axcella Health's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Axcella Health (Axcella Health) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 1270, Littleton, MA, USA, 01460
Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.
Executives
Paul Fehlner officer: Senior Vice President, CIPO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
William Hinshaw director, officer: President and CEO C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
L.p. Fpa, 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Fpa General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Societe Des Produits Nestle S.a. 10 percent owner AVENUE NESTLE 55, VEVEY V8 CH-1800
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Torben Straight Nissen director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Michael Rosenblatt director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martin Hendrix director C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Robert Crane officer: Chief Financial Officer 101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109